Preliminary results indicate that the immunizer does not need to be modified to protect against the strain; complete survey should be released in March
Preliminary data from a study carried out by Oxford University, in England, point out that the vaccine developed by the teaching center in partnership with AstraZeneca is effective against the Brazilian variant of coronavirus, found in Manaus, no Amazon. The strain, nicknamed “P.1“, Carries mutations that make the virus more contagious and more resistant to the disease’s antibodies. The data indicate that the vaccine will not need to be modified to protect against the variant, as reported by reporter Rodrigo Viga, from Young pan.
According to the source with knowledge of the research, which did not provide concrete data on effectiveness, the full study is expected to be released later this month. The report also contacted the Oswaldo Cruz Foundation (Fiocruz), responsible for conducting studies on the vaccine and producing the immunizer in Brazil, who informed that he does not participate in the research, only sends the samples to the company. The expectation is that National Health Surveillance Agency (Anvisa) make the definitive registration of the Oxford vaccine next week or, at the latest, by the end of March. Fiocruz’s goal is to produce more than 100 million doses by July, and in the second half, with inputs produced at the foundation, the forecast is to deliver over 110 million vaccines. The compound is being administered in Brazil, as well as the CoronaVac, produced by Butantan Institute.